Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

It’s Jewish Genetic Screening Awareness Week. Experts want you to get tested

Jews are at increased risk for several diseases. Here’s how to get screened for them

Jews who are considering starting a family or who are just worried about their own health are being encouraged to get tested, as Feb. 5 through Feb. 11 marks Jewish Genetic Screening Awareness Week. 

“When we talk about genetic screening, screening for a comprehensive panel of diseases for everyone is important,” said Karen Grinzaid, executive director of JScreen, a nonprofit dedicated to preventing genetic diseases among those with Jewish ancestry. “But I think it’s still very important for the Jewish community to be aware of the diseases that they are an increased risk for, and that these things have not gone away.”

People of Ashkenazi descent have been found to be at an elevated risk of several genetic disorders, most famously Tay-Sachs, a fatal condition that can manifest when two carriers have a child. Ashkenazi Jews are also at increased risk of Gaucher disease, which can affect a person’s spleen, liver and bone marrow, as well as cystic fibrosis, Bloom syndrome and others.

Though less well known, Sephardic and Mizrahi Jews are also at increased risk for a variety of genetic disorders, though which ones are often dependent on a family’s country of origin.

Jews also more frequently have genetic mutations that put them at increased risk of developing diseases like cancer. Mutations to the BRCA1 and BRCA2 genes can increase the odds of breast cancer and Jews have “a 10 times greater risk of carrying a mutation in one of these cancer susceptibility genes, compared to non-Jews,” said Grinzaid, even without a family history of cancer. 

Other genetic mutations that can be tested for include those linked to colon, bladder, prostate and pancreatic cancers, as well as melanoma. 

Grinzaid noted that many people put off getting tested due to anxiety over the results, but she emphasized that a positive result does not mean a 100% chance of developing a disease like cancer. Instead, knowing about risks can empower people to take preventative measures. She encouraged all Jews to seek out comprehensive genetic carrier testing, which looks for mutations common in the Ashkenazi, Sephardic and Mizrahi communities. Testing kits are available via the JScreen website.  

“There are steps that you can take to try to prevent cancer, or detect it early, when it’s treatable, and not end up in a situation that people don’t want to be in, where cancer is advanced,” said Grinzaid. 

As part of the awareness week, JScreen will be present on college campuses through Hillel and Chabad Houses to do educational and screening events. It will also be holding events at community organizations, JCCs and Federations. She encouraged anyone with a desire to have JScreen information available to their community to reach out.

“If a person has a connection with an organization that would be interested in bringing education in, that would be so helpful, and so life saving to their community.”

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version